New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable clinical and endoscopic remission through 92 weeks in adults with moderately to ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, highlights cost and treatment sequencing as some of ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

An article published by the Journal of the American Medical Association highlights recent updates made to the CONSORT ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using ...

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...

In the Phase Ib Beamion LUNG-1 clinical trial, zongertinib, an investigational irreversible tyrosine kinase inhibitor, ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...